Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276835 | 0.90 | P2RX3 (0.40) | S1PR1S1PR3ALDH1A1LMNA | |
| SCHEMBL4388255 | 0.71 | S1PR1 (0.40) | S1PR1S1PR3NPC1RAB9ALMNA | |
| SCHEMBL7055717 | 0.70 | S1PR1 (0.41) | S1PR1S1PR3ALDH1A1NPC1RAB9A | |
| SCHEMBL5969688 | 0.69 | S1PR1 (0.40) | S1PR1S1PR3LMNA | |
| SCHEMBL10474583 | 0.65 | CAPN1 (0.65) | S1PR1S1PR3LMNA | |
| SCHEMBL13798311 | 0.64 | LMNA (0.50) | S1PR1ALDH1A1RAB9ALMNA | |
| SCHEMBL10631698 | 0.64 | ALDH1A1 (0.52) | S1PR1S1PR3ALDH1A1LMNA | |
| SCHEMBL398161 | 0.64 | POLB (0.61) | ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL30421484 | 0.64 | POLB (0.61) | ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL14019746 | 0.64 | ITGB3 (0.50) | S1PR1S1PR3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2094311-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| WO-2008070291-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | S1PR1 259/4885S1PR3 272/4885ALDH1A1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.